During the past decade, Intermedius conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Intermedius" #1 collaborator was "Galapagos NV" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Intermedius" are "Sjogren's Syndrome" (1 trials) and "Systemic Lupus Erythematosus" (1 trials). Many other conditions were trialed in "Intermedius" in a lesser frequency.

Most popular intervention types in "Intermedius" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "BMS-986165" (1 trials), "Filgotinib" (1 trials), "Filgotinib placebo" (1 trials), "Lanraplenib" (1 trials) and "Lanraplenib placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Intermedius" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Intermedius". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Intermedius, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Intermedius, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".